[
  {
    "ts": "2025-11-20T04:43:15+00:00",
    "headline": "133-year-old big pharma company plans layoffs, files WARN notice",
    "summary": "Layoffs are increasing this year, and they're not limited to any one particular industry. We've previously seen high-profile layoffs from fast-growing technology stalwarts, including Amazon and Microsoft. Now, we've learned that Merck & Co., a 133-year-old drug manufacturer, also ...",
    "url": "https://www.thestreet.com/employment/133-year-old-big-pharma-company-plans-layoffs-files-warn-notice",
    "source": "TheStreet",
    "provider": "yfinance",
    "raw": {
      "id": "09005181-59d5-317f-ba35-7fbe6fea8efb",
      "content": {
        "id": "09005181-59d5-317f-ba35-7fbe6fea8efb",
        "contentType": "STORY",
        "title": "133-year-old big pharma company plans layoffs, files WARN notice",
        "description": "",
        "summary": "Layoffs are increasing this year, and they're not limited to any one particular industry. We've previously seen high-profile layoffs from fast-growing technology stalwarts, including Amazon and Microsoft. Now, we've learned that Merck & Co., a 133-year-old drug manufacturer, also ...",
        "pubDate": "2025-11-20T04:43:15Z",
        "displayTime": "2025-11-20T04:43:15Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/thestreet_881/5ce2ba0822fd139540aeb4684e445252",
          "originalWidth": 1200,
          "originalHeight": 800,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/9tshWq706Po_bbFa4QHS5w--~B/aD04MDA7dz0xMjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/thestreet_881/5ce2ba0822fd139540aeb4684e445252.cf.webp",
              "width": 1200,
              "height": 800,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/slv17lV7F4A7acUM4mCBwA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/thestreet_881/5ce2ba0822fd139540aeb4684e445252.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TheStreet",
          "url": "https://www.thestreet.com/"
        },
        "canonicalUrl": {
          "url": "https://www.thestreet.com/employment/133-year-old-big-pharma-company-plans-layoffs-files-warn-notice",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/133-old-big-pharma-company-044315865.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T12:00:00+00:00",
    "headline": "Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)",
    "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The pCPA negotiates on behalf of the provinces, territories, and federal drug programs serving as a critical step in bringing WINREVAIR® closer to public reimbursement.",
    "url": "https://finance.yahoo.com/news/merck-canada-pan-canadian-pharmaceutical-120000625.html",
    "source": "CNW Group",
    "provider": "yfinance",
    "raw": {
      "id": "a8d13f35-4482-3ec9-b88a-1a45520ddb13",
      "content": {
        "id": "a8d13f35-4482-3ec9-b88a-1a45520ddb13",
        "contentType": "STORY",
        "title": "Merck Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for WINREVAIR® (sotatercept)",
        "description": "",
        "summary": "Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that it has successfully completed negotiations with the pan‑Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR® (sotatercept). The pCPA negotiates on behalf of the provinces, territories, and federal drug programs serving as a critical step in bringing WINREVAIR® closer to public reimbursement.",
        "pubDate": "2025-11-20T12:00:00Z",
        "displayTime": "2025-11-20T12:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/cnwgroup.com/a31c818593c897369fcfa7d3a78ada87",
          "originalWidth": 148,
          "originalHeight": 44,
          "caption": "Merck Logo (PRNewsfoto/Merck)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/X5ECAuinb0c1ZNcmzcqSPA--~B/aD00NDt3PTE0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/cnwgroup.com/a31c818593c897369fcfa7d3a78ada87.cf.webp",
              "width": 148,
              "height": 44,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5dlM8l_JVcYrsCYpUwWlkA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/a31c818593c897369fcfa7d3a78ada87.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "CNW Group",
          "url": "http://www.newswire.ca/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/merck-canada-pan-canadian-pharmaceutical-120000625.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-canada-pan-canadian-pharmaceutical-120000625.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T11:57:00+00:00",
    "headline": "Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.",
    "summary": "Shares in the biotech company have surged on news of a big pharma takeover.",
    "url": "https://www.fool.com/investing/2025/11/20/cidara-therapeutics-is-up-85-heres-what-investors/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "64530ba8-3949-333c-836e-51b6a3d250e9",
      "content": {
        "id": "64530ba8-3949-333c-836e-51b6a3d250e9",
        "contentType": "STORY",
        "title": "Cidara Therapeutics Is Up Over 100%. Here's What Investors Need to Know.",
        "description": "",
        "summary": "Shares in the biotech company have surged on news of a big pharma takeover.",
        "pubDate": "2025-11-20T11:57:00Z",
        "displayTime": "2025-11-20T11:57:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/0ba667c2d6214259542a89f61e971a47",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A pair of biotech research scientists discuss their findings.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lkjfpLOK9N5WZPwFDmGVGA--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/0ba667c2d6214259542a89f61e971a47.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tirVL9trwaB5xe5whp1JHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/0ba667c2d6214259542a89f61e971a47.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/20/cidara-therapeutics-is-up-85-heres-what-investors/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cidara-therapeutics-over-100-heres-115700592.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CDTX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T13:00:00+00:00",
    "headline": "Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors",
    "summary": "Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development.",
    "url": "https://finance.yahoo.com/news/edgewise-therapeutics-appoints-commercial-biotech-130000855.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "edd5c31d-fc9b-37d4-bf25-5f5d8a92147d",
      "content": {
        "id": "edd5c31d-fc9b-37d4-bf25-5f5d8a92147d",
        "contentType": "STORY",
        "title": "Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors",
        "description": "",
        "summary": "Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology veteran Christopher Martin to its Board of Directors. Mr. Martin brings proven success across all key commercial functions, including marketing, sales, commercial operations, market access, trade and business development.",
        "pubDate": "2025-11-20T13:00:00Z",
        "displayTime": "2025-11-20T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/1eecb4e06f9917e887e792ed75d0efc5",
          "originalWidth": 400,
          "originalHeight": 87,
          "caption": "Edgewise Therapeutics (PRNewsfoto/Edgewise Therapeutics)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EdeRv124GxSy7lItWtWV5A--~B/aD04Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/1eecb4e06f9917e887e792ed75d0efc5.cf.webp",
              "width": 400,
              "height": 87,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/F30WXXSYf4ELiqW1ZEL2UA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/1eecb4e06f9917e887e792ed75d0efc5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/edgewise-therapeutics-appoints-commercial-biotech-130000855.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/edgewise-therapeutics-appoints-commercial-biotech-130000855.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "EWTX"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T14:08:05+00:00",
    "headline": "Stock Market Today: Dow Rallies As Nvidia Surges On Earnings; Jobs Report Surprises The Market (Live Coverage)",
    "summary": "Stock Market Today: The Dow Jones index rallied Thursday as Nvidia surged on earnings. The September jobs report came out better-than-expected.",
    "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-jobs-report-nvidia-stock-nvda-earnings/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "ecda93de-4a10-34ec-9a07-45b6e7e8d176",
      "content": {
        "id": "ecda93de-4a10-34ec-9a07-45b6e7e8d176",
        "contentType": "STORY",
        "title": "Stock Market Today: Dow Rallies As Nvidia Surges On Earnings; Jobs Report Surprises The Market (Live Coverage)",
        "description": "",
        "summary": "Stock Market Today: The Dow Jones index rallied Thursday as Nvidia surged on earnings. The September jobs report came out better-than-expected.",
        "pubDate": "2025-11-20T14:08:05Z",
        "displayTime": "2025-11-20T14:08:05Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/ecda93de-4a10-34ec-9a07-45b6e7e8d176/stock-market-today-dow.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/6681ba47464c8e51c9d4e56a07440051",
          "originalWidth": 1000,
          "originalHeight": 563,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Uevq5SWWjVFnFtdk5aL1RA--~B/aD01NjM7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/6681ba47464c8e51c9d4e56a07440051.cf.webp",
              "width": 1000,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmBdoSWJ8yktFaMh5vQNZw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/6681ba47464c8e51c9d4e56a07440051.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-sp500-nasdaq-jobs-report-nvidia-stock-nvda-earnings/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NVDA"
            },
            {
              "symbol": "PANW"
            },
            {
              "symbol": "NETTF"
            },
            {
              "symbol": "NTES"
            },
            {
              "symbol": "WMT"
            },
            {
              "symbol": "AMZN"
            },
            {
              "symbol": "IBM"
            },
            {
              "symbol": "QQQ"
            },
            {
              "symbol": "SPY"
            },
            {
              "symbol": "^DJI"
            },
            {
              "symbol": "^NDX"
            },
            {
              "symbol": "^SPX"
            },
            {
              "symbol": "CL=F"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "MSFT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T13:00:00+00:00",
    "headline": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
    "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
    "url": "https://www.barrons.com/articles/wp-bar-0001507322?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "8c561c75-a147-385f-98d0-4c38e35872d0",
      "content": {
        "id": "8c561c75-a147-385f-98d0-4c38e35872d0",
        "contentType": "STORY",
        "title": "This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.",
        "description": "",
        "summary": "For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date.  It’s a challenge that  Bristol Myers Squibb  is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022.  Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.",
        "pubDate": "2025-11-20T13:00:00Z",
        "displayTime": "2025-11-20T13:00:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/8c561c75-a147-385f-98d0-4c38e35872d0/this-drugmaker-is-too-cheap.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/dfaa0aa278f6a97780dafb57ba7fcc4e",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BDAtWtLWyCI7CySX9RsC6g--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/Barrons.com/dfaa0aa278f6a97780dafb57ba7fcc4e.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/u1UI6uVhsex1XVTnmmR5iA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/dfaa0aa278f6a97780dafb57ba7fcc4e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/wp-bar-0001507322?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BMY"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "SNY"
            },
            {
              "symbol": "SNYNF"
            },
            {
              "symbol": "MRK"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T14:45:00+00:00",
    "headline": "Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?",
    "summary": "The pharmaceutical giant's post-Keytruda plans continue to take shape.",
    "url": "https://www.fool.com/investing/2025/11/20/merck-is-buying-cidara-therapeutics-for-92-billion/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "c134bade-09d6-3267-bf2e-afa47ce50fcd",
      "content": {
        "id": "c134bade-09d6-3267-bf2e-afa47ce50fcd",
        "contentType": "STORY",
        "title": "Merck Is Buying Cidara Therapeutics for $9.2 Billion. Is This the Boost the Lagging Drugmaker Needs?",
        "description": "",
        "summary": "The pharmaceutical giant's post-Keytruda plans continue to take shape.",
        "pubDate": "2025-11-20T14:45:00Z",
        "displayTime": "2025-11-20T14:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/82e74613f3668980818cfd113d226d5d",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A healthcare worker vaccinates a patient.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/amR_7Z8XPezxfzWD8wo_Ng--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/82e74613f3668980818cfd113d226d5d.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oCCebWCImZJqvRy1I1ndcg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/82e74613f3668980818cfd113d226d5d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/11/20/merck-is-buying-cidara-therapeutics-for-92-billion/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/merck-buying-cidara-therapeutics-9-144500989.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            },
            {
              "symbol": "CDTX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T14:49:00+00:00",
    "headline": "MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC",
    "summary": "Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.",
    "url": "https://finance.yahoo.com/news/mrk-hiv-regimen-meets-goal-144900361.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "6f0f1bce-69bb-3d4b-995d-f57aeff9553f",
      "content": {
        "id": "6f0f1bce-69bb-3d4b-995d-f57aeff9553f",
        "contentType": "STORY",
        "title": "MRK HIV Regimen Meets Goal in New Study, Gains EU Nod for Keytruda SC",
        "description": "",
        "summary": "Merck reports strong new HIV study results showing non-inferiority of DOR/ISL to Gilead's Biktarvy and secures an EU approval for its faster-to-administer SC version of Keytruda.",
        "pubDate": "2025-11-20T14:49:00Z",
        "displayTime": "2025-11-20T14:49:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RRg0vYpNavphT7S8O9jT7w--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hIkvgr9e5vaptAEV_vkcVg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/1b28b8f55ab25205feceb1a2771a2b3a.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/mrk-hiv-regimen-meets-goal-144900361.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/mrk-hiv-regimen-meets-goal-144900361.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-20T14:40:02+00:00",
    "headline": "Here's Why Merck (MRK) is a Strong Value Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finance.yahoo.com/news/heres-why-merck-mrk-strong-144002940.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "d51a2d5c-0fa0-3382-89a6-687a305b34f6",
      "content": {
        "id": "d51a2d5c-0fa0-3382-89a6-687a305b34f6",
        "contentType": "STORY",
        "title": "Here's Why Merck (MRK) is a Strong Value Stock",
        "description": "",
        "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
        "pubDate": "2025-11-20T14:40:02Z",
        "displayTime": "2025-11-20T14:40:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba",
          "originalWidth": 900,
          "originalHeight": 745,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J2T_cDhaoaaQj0soPS_nNw--~B/aD03NDU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba.cf.webp",
              "width": 900,
              "height": 745,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/sWMlcbg78JI.iCrZWAER9Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/078b2d95159d12a337f09f2519ff10ba.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-merck-mrk-strong-144002940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-why-merck-mrk-strong-144002940.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "MRK"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]